US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US4943593A
(en)
|
1988-02-25 |
1990-07-24 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5252608A
(en)
|
1988-02-25 |
1993-10-12 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5059714A
(en)
|
1988-02-25 |
1991-10-22 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5182297A
(en)
|
1988-02-25 |
1993-01-26 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4965288A
(en)
|
1988-02-25 |
1990-10-23 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5021456A
(en)
|
1988-02-25 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5120764A
(en)
|
1988-11-01 |
1992-06-09 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4997854A
(en)
|
1989-08-25 |
1991-03-05 |
Trustees Of Boston University |
Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US20030125519A1
(en)
|
1990-08-27 |
2003-07-03 |
Peter Besmer |
Ligand for the c-kit receptor and methods of use thereof
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
DE4205148A1
(de)
|
1991-05-25 |
1993-01-21 |
Boehringer Mannheim Gmbh |
Monoklonale antikoerper gegen c-kit
|
DE69233254T2
(de)
|
1991-06-14 |
2004-09-16 |
Genentech, Inc., South San Francisco |
Humanisierter Heregulin Antikörper
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
WO1997027873A1
(en)
|
1996-01-30 |
1997-08-07 |
Brigham & Women's Hospital, Inc. |
Antibodies for modulating cd47-mediated neutrophil transmigration
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
JP2002506353A
(ja)
|
1997-06-24 |
2002-02-26 |
ジェネンテック・インコーポレーテッド |
ガラクトシル化糖タンパク質の方法及び組成物
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
DE69840412D1
(de)
|
1997-10-31 |
2009-02-12 |
Genentech Inc |
Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
|
ZA9810371B
(en)
|
1997-11-13 |
1999-08-30 |
Schering Corp |
Th2 cell depletion; compositions; methods.
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
WO1999029888A1
(en)
|
1997-12-05 |
1999-06-17 |
The Scripps Research Institute |
Humanization of murine antibody
|
CA2226962A1
(en)
|
1998-02-16 |
1999-08-16 |
Marie Sarfati |
Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
|
EP1068241B1
(en)
|
1998-04-02 |
2007-10-10 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
ES2569919T3
(es)
|
1999-04-09 |
2016-05-13 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de una molécula inmunofuncional
|
WO2001029246A1
(fr)
|
1999-10-19 |
2001-04-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production d'un polypeptide
|
EP1244707A1
(de)
|
1999-11-30 |
2002-10-02 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Antikörper gegen signal-regulator-proteine
|
US20030180714A1
(en)
|
1999-12-15 |
2003-09-25 |
Genentech, Inc. |
Shotgun scanning
|
CA2785941C
(en)
|
2000-10-06 |
2017-01-10 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody composition-producing cell
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
TWI313299B
(en)
|
2000-11-30 |
2009-08-11 |
Medarex Inc |
Transgenic transchromosomal rodents for making human antibodies
|
AU2002315052A1
(en)
|
2001-05-15 |
2002-11-25 |
Emory University |
Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
|
NZ603111A
(en)
|
2001-08-03 |
2014-05-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
FR2828206B1
(fr)
|
2001-08-03 |
2004-09-24 |
Centre Nat Rech Scient |
Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
|
BR0213761A
(pt)
|
2001-10-25 |
2005-04-12 |
Genentech Inc |
Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
EP1498491A4
(en)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
CA2481657A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
CA2488441C
(en)
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
HU227217B1
(en)
|
2002-12-16 |
2010-11-29 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
CA2510003A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
JPWO2004080462A1
(ja)
|
2003-03-10 |
2006-06-08 |
エーザイ株式会社 |
c−Kitキナーゼ阻害剤
|
AU2004268621C1
(en)
|
2003-08-29 |
2011-08-18 |
Exelixis, Inc. |
c-Kit modulators and methods of use
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
US20070134759A1
(en)
|
2003-10-09 |
2007-06-14 |
Harue Nishiya |
Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
|
AU2004283299B2
(en)
|
2003-10-22 |
2009-06-18 |
Alder Biopharmaceuticals, Inc. |
Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
|
RS54450B1
(en)
|
2003-11-05 |
2016-06-30 |
Roche Glycart Ag |
ANTIGEN-BINDING MOLECULES WITH INCREASED BINDING AFFINITY FOR FC RECEPTOR AND EFFECTOR FUNCTION
|
CA2545166A1
(en)
|
2003-11-11 |
2005-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized anti-cd47 antibody
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
WO2005097832A2
(en)
|
2004-03-31 |
2005-10-20 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
CN101031569B
(zh)
|
2004-05-13 |
2011-06-22 |
艾科斯有限公司 |
作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
|
NZ550810A
(en)
|
2004-05-19 |
2009-05-31 |
Immunocore Ltd |
High affinity NY-ESO T cell receptor
|
CA2570817A1
(en)
|
2004-06-17 |
2006-01-26 |
Plexxikon, Inc. |
Azaindoles modulating c-kit activity and uses therefor
|
WO2006031221A1
(en)
|
2004-09-13 |
2006-03-23 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Compositions comprising t cell receptors and methods of use thereof
|
AU2005316091B2
(en)
|
2004-12-17 |
2011-12-01 |
Merck Canada Inc. |
2-(phenyl or heterocyclic)-1H-phenantrho[9,10-D]imidazoles as mPGES-1 inhibitors
|
US7442716B2
(en)
|
2004-12-17 |
2008-10-28 |
Merck Frosst Canada Ltd. |
2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
|
DE602006011574D1
(de)
|
2005-01-27 |
2010-02-25 |
Five Prime Therapeutics Inc |
Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
|
US20090142345A1
(en)
|
2005-03-15 |
2009-06-04 |
Takeda Pharmaceutical Company Limited |
Prophylactic/therapeutic agent for cancer
|
AU2006247520A1
(en)
|
2005-05-18 |
2006-11-23 |
Wyeth |
3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same
|
WO2006124944A1
(en)
|
2005-05-18 |
2006-11-23 |
Wyeth |
4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
|
US7923538B2
(en)
|
2005-07-22 |
2011-04-12 |
Kyowa Hakko Kirin Co., Ltd |
Recombinant antibody composition
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
|
TWI404537B
(zh)
|
2005-08-19 |
2013-08-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
|
EP1930433B1
(en)
|
2005-09-13 |
2016-03-16 |
Mie University |
T-cell receptor and nucleic acid encoding the receptor
|
WO2007044756A2
(en)
*
|
2005-10-11 |
2007-04-19 |
Icos Corporation |
Monoclonal antibodies recognizing human ccr8
|
EP2465870A1
(en)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
WO2007064919A2
(en)
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
KR100788161B1
(ko)
|
2006-01-06 |
2007-12-21 |
(주)아모레퍼시픽 |
벤즈이미다졸 아민 유도체 또는 아미노퀴놀린 유도체를 함유하는 피부 미백용 조성물
|
TW200740776A
(en)
|
2006-02-06 |
2007-11-01 |
Osi Pharm Inc |
N-phenylbenzotriazolyl c-kit inhibitors
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
WO2007124589A1
(en)
|
2006-05-02 |
2007-11-08 |
Merck Frosst Canada Ltd. |
Methods for treating or preventing neoplasias
|
EP2016101A2
(en)
|
2006-05-09 |
2009-01-21 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
CA2652570A1
(en)
|
2006-05-15 |
2007-11-22 |
Viral Logic Systems Technology Corp. |
Cd47 related compositions and methods for treating immunological diseases and disorders
|
CN106075388B
(zh)
|
2006-05-22 |
2021-06-29 |
加利福尼亚大学董事会 |
用于输送一氧化氮的组合物和方法
|
ITMI20061053A1
(it)
|
2006-05-30 |
2007-11-30 |
Manuli Rubber Ind Spa |
Raccordo per tubi flessibili per applicazioni oleodinamiche,industriali e aria condizionata,avente caratteristiche di tenuta migliorate.
|
WO2008005877A2
(en)
|
2006-06-30 |
2008-01-10 |
Board Of Regents, The University Of Texas System |
Inhibitors of c-kit and uses thereof
|
WO2008073160A2
(en)
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Methods for converting or inducing protective immunity
|
DE102006058450A1
(de)
|
2006-12-12 |
2008-06-19 |
Eberhard-Karls-Universität Tübingen |
Zubereitungen zur Hemmung der Prostaglandin E2 Synthese
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
KR101578940B1
(ko)
|
2007-01-24 |
2015-12-18 |
교와 핫꼬 기린 가부시키가이샤 |
이펙터 활성이 증강된 유전자 재조합 항체 조성물
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
AR067182A1
(es)
|
2007-06-29 |
2009-09-30 |
Gilead Sciences Inc |
Moduladores del receptor 7 tipo toll
|
CN105330743B
(zh)
|
2007-08-02 |
2019-05-28 |
吉利德生物制剂公司 |
Lox和loxl2抑制剂及其应用
|
US20100239578A1
(en)
|
2007-10-11 |
2010-09-23 |
University Health Network |
Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
|
UY31468A1
(es)
|
2007-11-15 |
2009-07-17 |
|
Derivados bis-(sulfonilamino) en terapia 065
|
TW200930369A
(en)
|
2007-11-15 |
2009-07-16 |
Astrazeneca Ab |
Bis-(sulfonylamino) derivatives in therapy
|
US20090163586A1
(en)
|
2007-12-20 |
2009-06-25 |
Astrazeneca Ab |
Bis-(Sulfonylamino) Derivatives in Therapy 205
|
WO2009103778A1
(en)
|
2008-02-19 |
2009-08-27 |
Novasaid Ab |
Compounds and methods
|
WO2009117987A2
(de)
|
2008-03-26 |
2009-10-01 |
Universität Tübingen |
Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g
|
WO2009130242A1
(en)
|
2008-04-23 |
2009-10-29 |
Novasaid Ab |
Low molecular weight derivatives and use thereof in treatment of prostaglandin e synthase related diseases
|
EP2119705A1
(en)
|
2008-05-14 |
2009-11-18 |
AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. |
3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
|
DE102008027331A1
(de)
|
2008-06-07 |
2009-12-10 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase
|
DE102008015432A1
(de)
|
2008-06-12 |
2009-12-17 |
Eberhard-Karls-Universität Tübingen |
Verwendung von Pirinixinsäure-Derivaten zur Hemmung der Prostaglandin E2 Synthese
|
ES2438496T3
(es)
|
2008-08-01 |
2014-01-17 |
Ventirx Pharmaceuticals, Inc. |
Formulaciones de agonistas de receptores de tipo toll y su uso
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
UY32138A
(es)
|
2008-09-25 |
2010-04-30 |
Boehringer Ingelheim Int |
Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
ES2467108T3
(es)
|
2008-12-09 |
2014-06-11 |
Gilead Sciences, Inc. |
Moduladores de receptores tipo toll
|
EP2379584A1
(en)
|
2008-12-19 |
2011-10-26 |
Novartis AG |
Soluble polypeptides for use in treating autoimmune and inflammatory disorders
|
WO2010083253A2
(en)
|
2009-01-14 |
2010-07-22 |
Viral Logic Systems Technology Corp. |
Cd47 related compositions and methods for treating immunological diseases and disorders
|
UY32470A
(es)
|
2009-03-05 |
2010-10-29 |
Boehringer Ingelheim Int |
Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
|
WO2010106431A2
(en)
|
2009-03-20 |
2010-09-23 |
Ludwig Institute For Cancer Research Ltd |
High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof
|
TWI625121B
(zh)
|
2009-07-13 |
2018-06-01 |
基利科學股份有限公司 |
調節細胞凋亡信號之激酶的抑制劑
|
WO2011022508A2
(en)
|
2009-08-18 |
2011-02-24 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
US8524702B2
(en)
|
2009-08-18 |
2013-09-03 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
WO2011023812A1
(en)
|
2009-08-27 |
2011-03-03 |
Novasaid Ab |
Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
|
IN2012DN02984A
(es)
|
2009-10-22 |
2015-07-31 |
Gilead Sciences Inc |
|
JP5579862B2
(ja)
|
2009-10-23 |
2014-08-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ミクロソームプロスタグランジンe2シンターゼ−1のインヒビター
|
CN102869682B
(zh)
|
2009-11-18 |
2016-10-19 |
曼康公司 |
单克隆抗体及其诊断用途
|
WO2011076781A1
(en)
|
2009-12-22 |
2011-06-30 |
Novartis Ag |
Tetravalent cd47-antibody constant region fusion protein for use in therapy
|
WO2011097513A1
(en)
|
2010-02-04 |
2011-08-11 |
Gilead Biologics, Inc |
Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
|
US9717777B2
(en)
*
|
2010-05-05 |
2017-08-01 |
Rappaport Family Institute For Research In The Medical Sciences |
Use of CCL1 in therapy
|
PL3789038T3
(pl)
|
2010-05-14 |
2023-01-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
US8759537B2
(en)
|
2010-08-20 |
2014-06-24 |
Boehringer Ingelheim International Gmbh |
3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
|
US8586604B2
(en)
|
2010-08-20 |
2013-11-19 |
Boehringer Ingelheim International Gmbh |
Inhibitors of the microsomal prostaglandin E2 synthase-1
|
KR101518144B1
(ko)
|
2010-08-27 |
2015-05-28 |
길리아드 바이오로직스, 인크. |
매트릭스 메탈로프로테이나제 9에 대한 항체
|
CN103237549A
(zh)
|
2010-10-01 |
2013-08-07 |
帆德制药股份有限公司 |
过敏性疾病的治疗方法
|
CN107970451A
(zh)
|
2010-10-01 |
2018-05-01 |
帆德制药股份有限公司 |
Tlr激动剂和联合治疗的治疗应用
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
LT2649086T
(lt)
|
2010-12-09 |
2017-11-10 |
The Trustees Of The University Of Pennsylvania |
Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui
|
US8466186B2
(en)
|
2010-12-10 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Compounds
|
UY33779A
(es)
|
2010-12-10 |
2012-07-31 |
Boehringer Ingelheim Int |
?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
|
US9096532B2
(en)
|
2010-12-13 |
2015-08-04 |
The Regents Of The University Of California |
Pyrazole inhibitors of COX-2 and sEH
|
AR084174A1
(es)
|
2010-12-21 |
2013-04-24 |
Lilly Co Eli |
Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
|
JP5985509B2
(ja)
|
2011-01-12 |
2016-09-06 |
ベンティアールエックス ファーマシューティカルズ, インコーポレイテッドVentiRx Pharmaceuticals,Inc. |
Toll様受容体調節薬としての置換ベンゾアゼピン
|
AU2012205490B2
(en)
|
2011-01-12 |
2017-02-02 |
Array Biopharma, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
WO2012110860A1
(en)
|
2011-02-17 |
2012-08-23 |
Glenmark Pharmaceuticals S.A. |
TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
|
ES2691745T3
(es)
|
2011-04-08 |
2018-11-28 |
Janssen Sciences Ireland Uc |
Derivados de pirimidina para el tratamiento de infecciones víricas
|
AR086044A1
(es)
|
2011-05-12 |
2013-11-13 |
Imclone Llc |
Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
|
DK2709989T3
(en)
|
2011-05-18 |
2018-04-09 |
Janssen Sciences Ireland Uc |
QUINAZOLINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND ADDITIONAL DISEASES
|
AR086254A1
(es)
|
2011-05-26 |
2013-11-27 |
Lilly Co Eli |
Derivados de imidazol utiles para el tratamiento de artritis
|
WO2012170250A1
(en)
|
2011-06-07 |
2012-12-13 |
Radiation Control Technologies, Inc. |
Morpholino oligonucleotides capable of inhibiting cd47-mediated cellular damage and uses thereof
|
WO2012172341A2
(en)
|
2011-06-13 |
2012-12-20 |
Ith Immune Therapy Holdings |
Treating cancer
|
AU2012295805B2
(en)
|
2011-08-18 |
2017-05-04 |
Nippon Shinyaku Co., Ltd. |
Heterocyclic derivative and pharmaceutical drug
|
EP2749572A4
(en)
|
2011-08-23 |
2015-04-01 |
Chugai Pharmaceutical Co Ltd |
NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
PL2755997T3
(pl)
|
2011-09-15 |
2019-01-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7
|
WO2013041865A1
(en)
|
2011-09-22 |
2013-03-28 |
Immunocore Limited |
T cell receptors
|
EP2763994A4
(en)
|
2011-10-04 |
2015-08-26 |
Gilead Calistoga Llc |
NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
|
WO2013056352A1
(en)
|
2011-10-19 |
2013-04-25 |
University Health Network |
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
|
WO2013072825A1
(en)
|
2011-11-16 |
2013-05-23 |
Glenmark Pharmaceuticals S.A. |
Phtalazinone derivatives as mpegs -1 inhibitors
|
ES2649410T3
(es)
|
2011-12-21 |
2018-01-11 |
Novira Therapeutics Inc. |
Agentes antivirales para la hepatitis B
|
EP2804617B9
(en)
|
2012-01-17 |
2021-04-07 |
The Board of Trustees of the Leland Stanford Junior University |
High affinity sirp-alpha reagents
|
UY34573A
(es)
|
2012-01-27 |
2013-06-28 |
Gilead Sciences Inc |
Inhibidor de la quinasa que regula la señal de la apoptosis
|
WO2013116562A1
(en)
|
2012-02-03 |
2013-08-08 |
Gilead Calistoga Llc |
Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
|
MX360772B
(es)
|
2012-02-06 |
2018-11-15 |
Inhibrx Inc |
Anticuerpos cd47 y metodos de uso de los mismos.
|
US9133192B2
(en)
|
2012-02-08 |
2015-09-15 |
Janssen Sciences Ireland Uc |
Piperidino-pyrimidine derivatives for the treatment of viral infections
|
WO2013118071A1
(en)
|
2012-02-09 |
2013-08-15 |
Glenmark Pharmaceuticals S.A. |
BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
|
WO2013131010A2
(en)
|
2012-03-02 |
2013-09-06 |
Icahn School Of Medicine At Mount Sinai |
Function of chemokine receptor ccr8 in melanoma metastasis
|
WO2013153535A1
(en)
|
2012-04-13 |
2013-10-17 |
Glenmark Pharmaceuticals S.A. |
TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
|
TWI568722B
(zh)
|
2012-06-15 |
2017-02-01 |
葛蘭馬克製藥公司 |
作爲mPGES-1抑制劑之***酮化合物
|
SG11201500814UA
(en)
|
2012-08-10 |
2015-03-30 |
Janssen Sciences Ireland Uc |
Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
|
CN104981247A
(zh)
|
2012-09-06 |
2015-10-14 |
普莱希科公司 |
用于激酶调节的化合物和方法及其适应症
|
UY35044A
(es)
|
2012-09-24 |
2014-04-30 |
Gilead Sciences Inc |
ANTICUERPOS ANTI-dDr1
|
CA2884478C
(en)
|
2012-10-10 |
2021-02-16 |
Janssen Sciences Ireland Uc |
Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
|
IN2015DN03795A
(es)
|
2012-10-24 |
2015-10-02 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
EP2911669B1
(en)
|
2012-10-26 |
2024-04-10 |
The University of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
CN105051018B
(zh)
|
2012-11-16 |
2019-09-20 |
爱尔兰詹森科学公司 |
用于治疗病毒性感染的杂环的经取代的2-氨基-喹唑啉衍生物
|
AU2013353763B2
(en)
|
2012-12-03 |
2018-09-13 |
Novimmune S.A. |
Anti-CD47 antibodies and methods of use thereof
|
SG11201504469XA
(en)
|
2012-12-12 |
2015-07-30 |
Vasculox Inc |
Therapeutic cd47 antibodies
|
PE20151280A1
(es)
|
2012-12-21 |
2015-09-12 |
Plexxikon Inc |
Compuestos y metodos para la modulacion de quinasas y sus indicaciones
|
ES2677919T3
(es)
|
2012-12-21 |
2018-08-07 |
Gilead Calistoga Llc |
Aminoalquil-quinazolonas sustituidas con pirimidina como inhibidores de la fosfatidilinositol 3-quinasa
|
NZ708870A
(en)
|
2012-12-21 |
2016-09-30 |
Gilead Calistoga Llc |
Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
|
US10385116B2
(en)
|
2013-01-07 |
2019-08-20 |
Omniox, Inc. |
Polymeric forms of H-NOX proteins
|
CA2899679C
(en)
|
2013-01-29 |
2023-03-21 |
Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch |
High avidity antigen recognizing constructs
|
MY191389A
(en)
|
2013-02-21 |
2022-06-22 |
Janssen Sciences Ireland Uc |
2-aminopyrimidine derivatives for the treatment of viral infections
|
WO2014165128A2
(en)
|
2013-03-12 |
2014-10-09 |
Novira Therapeutics, Inc. |
Hepatitis b antiviral agents
|
AU2014235816B2
(en)
|
2013-03-15 |
2018-05-17 |
Bristol-Myers Squibb Company |
IDO inhibitors
|
WO2014167444A1
(en)
|
2013-04-08 |
2014-10-16 |
Glenmark Pharmaceuticals S.A. |
SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
|
TWI644909B
(zh)
|
2013-06-14 |
2018-12-21 |
基利科學股份有限公司 |
磷脂酸肌醇3-激酶抑制劑
|
GB201313377D0
(en)
|
2013-07-26 |
2013-09-11 |
Adaptimmune Ltd |
T cell receptors
|
WO2015059618A1
(en)
|
2013-10-22 |
2015-04-30 |
Glenmark Pharmaceuticals S.A. |
SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
|
US9290505B2
(en)
|
2013-12-23 |
2016-03-22 |
Gilead Sciences, Inc. |
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
|
US9771369B2
(en)
|
2014-03-04 |
2017-09-26 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
AU2015229448B2
(en)
|
2014-03-11 |
2020-09-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
|
ES2871027T3
(es)
|
2014-03-27 |
2021-10-28 |
Eicosis Llc |
Inhibidores potentes de la epóxido hidrolasa soluble
|
CA2945305C
(en)
|
2014-04-10 |
2023-10-17 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Method and compositions for cellular immunotherapy
|
AU2015246577B2
(en)
|
2014-04-14 |
2019-10-03 |
Jiangsu Hengrui Medicine Co., Ltd. |
Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof
|
US10087259B1
(en)
|
2014-04-28 |
2018-10-02 |
Memorial Sloan Kettering Cancer Center |
Depleting tumor-specific tregs
|
CN106413751A
(zh)
*
|
2014-05-21 |
2017-02-15 |
辉瑞大药厂 |
用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
|
GB2532619A
(en)
|
2014-08-08 |
2016-05-25 |
Alexo Therapeutics Int |
Sirp-Alpha Variant Constructs And Uses Thereof
|
EP3188758B1
(en)
|
2014-08-08 |
2023-10-04 |
The Board of Trustees of the Leland Stanford Junior University |
Sirp alpha-antibody fusion proteins
|
ES2751915T5
(es)
|
2014-08-15 |
2022-12-23 |
Merck Patent Gmbh |
Proteínas de fusión de inmunoglobulina con SIRP alfa
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
GB201417803D0
(en)
|
2014-10-08 |
2014-11-19 |
Adaptimmune Ltd |
T cell receptors
|
AR102361A1
(es)
|
2014-10-29 |
2017-02-22 |
Lilly Co Eli |
Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
|
JO3581B1
(ar)
|
2014-10-29 |
2020-07-05 |
Lilly Co Eli |
مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي
|
AU2015350190B2
(en)
|
2014-11-18 |
2021-08-05 |
Janssen Pharmaceutica Nv |
CD47 antibodies, methods, and uses
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
CA2966234A1
(en)
|
2014-12-15 |
2016-06-23 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
MX2017008819A
(es)
|
2014-12-30 |
2018-03-14 |
Celgene Corp |
Anticuerpos anti-cd47 y usos de los mismos.
|
EP3265125A4
(en)
|
2015-03-04 |
2018-11-07 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind cd47
|
CA3214521A1
(en)
|
2015-03-10 |
2016-09-15 |
ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) |
T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
|
SG11201707583RA
(en)
|
2015-03-17 |
2017-10-30 |
Omniox Inc |
MODULATION OF TUMOR IMMUNITY BY PROTEIN-MEDIATED 0<sb>2</sb> DELIVERY
|
WO2016179399A1
(en)
|
2015-05-06 |
2016-11-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity cd47 analogs
|
CN106188275A
(zh)
|
2015-05-06 |
2016-12-07 |
广州市香雪制药股份有限公司 |
识别ny-eso-1抗原短肽的t细胞受体
|
CN115109158A
(zh)
|
2015-05-07 |
2022-09-27 |
阿吉纳斯公司 |
抗ox40抗体及其使用方法
|
EP3297673A4
(en)
|
2015-05-22 |
2019-05-08 |
Memorial Sloan-Kettering Cancer Center |
FOR A PRAME-PEPTIDE SPECIFIC T-CELL RECEPTOR-SIMILAR ANTIBODIES
|
CN104804093A
(zh)
|
2015-05-27 |
2015-07-29 |
江苏春申堂药业有限公司 |
一种针对cd47的单域抗体
|
US20180161368A1
(en)
|
2015-05-29 |
2018-06-14 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
US10618976B2
(en)
|
2015-06-16 |
2020-04-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRP-α agonist antibody
|
US20190382504A1
(en)
|
2015-06-24 |
2019-12-19 |
Eureka Therapeutics, Inc. |
Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
|
CA2989684A1
(en)
|
2015-06-25 |
2016-12-29 |
University Health Network |
Hpk1 inhibitors and methods of using same
|
MY185014A
(en)
|
2015-08-07 |
2021-04-30 |
Alx Oncology Inc |
Contructs having a sirp-alpha domain or variant thereof
|
CA2997749A1
(en)
|
2015-09-09 |
2017-03-16 |
Immune Design Corp. |
Ny-eso-1 specific tcrs and methods of use thereof
|
SG10202110257UA
(en)
|
2015-09-17 |
2021-10-28 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
BR112018005322A2
(pt)
|
2015-09-18 |
2018-12-11 |
Arch Oncology, Inc. |
anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
|
AU2016326423A1
(en)
|
2015-09-21 |
2018-04-26 |
Erasmus University Medical Center |
Anti-CD47 antibodies and methods of use
|
CN106632660B
(zh)
|
2015-11-04 |
2021-01-29 |
广东香雪精准医疗技术有限公司 |
识别ny-eso-1抗原短肽的tcr
|
WO2017096281A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
WO2017096276A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
CA3007233A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
US20200123265A1
(en)
|
2015-12-02 |
2020-04-23 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
AU2016364891A1
(en)
|
2015-12-03 |
2018-06-07 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
GB201522592D0
(en)
|
2015-12-22 |
2016-02-03 |
Immunocore Ltd |
T cell receptors
|
CA3177526A1
(en)
|
2016-01-11 |
2017-07-20 |
Forty Seven, Inc. |
Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
|
WO2017147410A1
(en)
|
2016-02-25 |
2017-08-31 |
Amgen Inc. |
Compounds that inhibit mcl-1 protein
|
US10858338B2
(en)
|
2016-03-15 |
2020-12-08 |
The Regents Of The University Of California |
Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH)
|
CN107286077B
(zh)
|
2016-04-01 |
2021-04-02 |
合肥中科普瑞昇生物医药科技有限公司 |
一种选择性的c-kit激酶抑制剂
|
SG11201808750PA
(en)
|
2016-04-08 |
2018-11-29 |
Adaptimmune Ltd |
T cell receptors
|
PT3440105T
(pt)
|
2016-04-08 |
2022-05-31 |
Immunocore Ltd |
Recetores de células t
|
EP3440102A1
(en)
|
2016-04-08 |
2019-02-13 |
Adaptimmune Limited |
T cell receptors
|
JP7240176B2
(ja)
|
2016-04-08 |
2023-03-15 |
アダプティミューン・リミテッド |
T細胞受容体
|
CN109071664B
(zh)
|
2016-04-14 |
2023-02-21 |
Ose免疫疗法 |
新型抗-SIRPa抗体及其治疗应用
|
DK3448882T3
(da)
|
2016-04-26 |
2022-02-21 |
Us Health |
Anti-kk-lc-1-t-cellereceptorer
|
AR112048A1
(es)
|
2016-05-09 |
2019-09-18 |
Celgene Corp |
Anticuerpos cd47 y métodos de uso de los mismos
|
EP3243522A1
(en)
|
2016-05-10 |
2017-11-15 |
Université Pierre et Marie Curie (Paris 6) |
Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
|
CN109311848B
(zh)
|
2016-06-07 |
2022-02-01 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|
CN106084052B
(zh)
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
EP3478674B1
(en)
|
2016-06-30 |
2020-05-13 |
Gilead Sciences, Inc. |
4,6-diaminoquinazolines as cot modulators and methods of use thereof
|
KR20230142658A
(ko)
|
2016-08-03 |
2023-10-11 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
|
WO2018049214A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
|
US10280164B2
(en)
|
2016-09-09 |
2019-05-07 |
Incyte Corporation |
Pyrazolopyridone compounds and uses thereof
|
JP7076432B2
(ja)
|
2016-09-09 |
2022-05-27 |
インサイト・コーポレイション |
Hpk1調節薬としてのピラゾロピリジン誘導体及びがんの治療のためのその用法
|
AR109595A1
(es)
|
2016-09-09 |
2018-12-26 |
Incyte Corp |
Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
CA2999058C
(en)
|
2016-10-20 |
2024-03-12 |
I-Mab |
Novel cd47 monoclonal antibodies and uses thereof
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
TW202321301A
(zh)
*
|
2016-11-02 |
2023-06-01 |
美商永斯醫療股份有限公司 |
Pd-1之抗體及其用途
|
WO2018089508A2
(en)
|
2016-11-08 |
2018-05-17 |
Ablexis, Llc |
Anti-cd47 antibodies
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
WO2018097951A1
(en)
|
2016-11-22 |
2018-05-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3/a6 antibodies
|
AU2017363257B2
(en)
|
2016-11-22 |
2021-08-19 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
CN108779179B
(zh)
|
2016-11-28 |
2022-02-08 |
江苏恒瑞医药股份有限公司 |
Cd47抗体、其抗原结合片段及其医药用途
|
US11180482B2
(en)
|
2016-11-30 |
2021-11-23 |
Ariad Pharmaceuticals, Inc. |
Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
|
JP7173971B2
(ja)
|
2016-12-09 |
2022-11-16 |
アレクトル エルエルシー |
抗SIRP-α抗体及びその使用方法
|
WO2018112033A1
(en)
*
|
2016-12-13 |
2018-06-21 |
President And Fellows Of Harvard College |
Methods and compositions for targeting tumor-infiltrating tregs
|
KR102594476B1
(ko)
|
2016-12-15 |
2023-10-27 |
어리어드 파마슈티칼스, 인코포레이티드 |
C-kit 억제제로서의 아미노티아졸 화합물
|
EA201991197A1
(ru)
|
2016-12-15 |
2020-01-13 |
Ариад Фармасьютикалз, Инк. |
БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
|
KR20230119252A
(ko)
|
2016-12-23 |
2023-08-16 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를위한 화합물 및 방법
|
KR20190103226A
(ko)
|
2017-01-13 |
2019-09-04 |
아게누스 인코포레이티드 |
Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법
|
UA126571C2
(uk)
*
|
2017-01-24 |
2022-11-02 |
Ай-Маб Байофарма Юес Лімітед |
Антитіло до cd73 та його застосування
|
CN110461872B
(zh)
|
2017-01-26 |
2023-09-26 |
再鼎医药(上海)有限公司 |
Cd47抗原结合单元及其用途
|
US20180215731A1
(en)
|
2017-01-31 |
2018-08-02 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
WO2018167147A1
(en)
|
2017-03-15 |
2018-09-20 |
F. Hoffmann-La Roche Ag |
Azaindoles as inhibitors of hpk1
|
MX2019010972A
(es)
|
2017-03-15 |
2019-12-02 |
Hutchinson Fred Cancer Res |
Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
|
US10988466B2
(en)
|
2017-03-23 |
2021-04-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Heterocyclic derivatives useful as SHP2 inhibitors
|
DE102017106305A1
(de)
|
2017-03-23 |
2018-09-27 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
|
CN110573180B
(zh)
|
2017-03-29 |
2021-08-17 |
盐野义制药株式会社 |
癌症治疗用药物组合物
|
JP6453507B2
(ja)
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Mcl−1タンパク質を阻害する化合物
|
JP7154221B2
(ja)
|
2017-03-30 |
2022-10-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Hpk1の阻害剤としてのナフチリジン
|
AU2018243770A1
(en)
|
2017-03-30 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Isoquinolines as inhibitors of HPK1
|
JP7160833B2
(ja)
|
2017-04-13 |
2022-10-25 |
サイロパ ビー.ブイ. |
抗sirpアルファ抗体
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
TWI710574B
(zh)
|
2017-05-16 |
2020-11-21 |
荷蘭商拜恩迪斯公司 |
抗訊號調節蛋白α(SIRPα)抗體
|
EP3636761A4
(en)
|
2017-06-05 |
2021-03-03 |
Mie University |
ANTIGEN BINDING PROTEIN RECOGNIZING A MAGE-DERIVED PEPTIDE-A4
|
WO2018223909A1
(zh)
|
2017-06-05 |
2018-12-13 |
成都海创药业有限公司 |
一种嵌合分子及其制备和应用
|
WO2018226542A1
(en)
|
2017-06-09 |
2018-12-13 |
Arvinas, Inc. |
Modulators of proteolysis and associated methods of use
|
WO2018237026A1
(en)
|
2017-06-20 |
2018-12-27 |
C4 Therapeutics, Inc. |
N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
|
CN109096395B
(zh)
|
2017-06-20 |
2022-06-24 |
华兰生物工程股份有限公司 |
阻断型cd47纳米抗体及其用途
|
GB201709866D0
(en)
|
2017-06-20 |
2017-08-02 |
Immunocore Ltd |
T cell receptors
|
CA3071193A1
(en)
|
2017-07-26 |
2019-01-31 |
Forty Seven, Inc. |
Anti-sirp-alpha antibodies and related methods
|
CN111183155B
(zh)
|
2017-08-02 |
2024-02-20 |
凡恩世制药(北京)有限公司 |
抗cd47抗体及其用途
|
AU2018316742A1
(en)
|
2017-08-18 |
2020-03-19 |
Centessa Pharmaceuticals (Uk) Limited |
Binding agents
|
CN109422811A
(zh)
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
CN108503708B
(zh)
|
2017-09-01 |
2021-07-30 |
北京智仁美博生物科技有限公司 |
抗人cd47抗体及其用途
|
CN109422726B
(zh)
|
2017-09-04 |
2022-10-28 |
华东理工大学 |
CD47/SIRPα的阻断剂及其应用
|
CN111315735B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
二氢苯并咪唑酮
|
EP3679028A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydroquinolinones
|
US20200239530A1
(en)
|
2017-09-27 |
2020-07-30 |
Vividion Therapeutics, Inc. |
Compounds and methods of modulating protein degradation
|
EP3676268A1
(en)
|
2017-10-20 |
2020-07-08 |
Dana-Farber Cancer Institute, Inc. |
Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
|
WO2019084026A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
US11866785B2
(en)
|
2017-10-27 |
2024-01-09 |
Board Of Regents, The University Of Texas System |
Tumor specific antibodies and T-cell receptors and methods of identifying the same
|
JP2021500926A
(ja)
|
2017-11-01 |
2021-01-14 |
ハミングバード・バイオサイエンス・ホールディングス・プライベート・リミテッド |
Cd47抗原結合分子
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
WO2019103203A1
(ko)
|
2017-11-24 |
2019-05-31 |
주식회사 젬백스앤카엘 |
신규 펩티드 및 이를 포함한 조성물
|
SG11202004864TA
(en)
|
2017-12-01 |
2020-06-29 |
Seattle Genetics Inc |
Cd47 antibodies and uses thereof for treating cancer
|
CN109879957B
(zh)
|
2017-12-06 |
2022-03-18 |
香雪生命科学技术(广东)有限公司 |
针对prame的高亲和力t细胞受体
|
JP7438955B2
(ja)
|
2018-01-12 |
2024-02-27 |
オーリジーン オンコロジー リミテッド |
Cd47シグナル伝達経路の阻害剤としての1,2,4-オキサジアゾール化合物
|
US20210070855A1
(en)
|
2018-01-24 |
2021-03-11 |
Nanjing Legend Biotech Co., Ltd. |
Anti-cd47 antibodies that do not cause significant red blood cell agllutination
|
WO2019157098A1
(en)
*
|
2018-02-06 |
2019-08-15 |
Advaxis, Inc. |
Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use
|
GB201802201D0
(en)
|
2018-02-09 |
2018-03-28 |
Ultrahuman Five Ltd |
Binding agents
|
TWI796596B
(zh)
|
2018-02-13 |
2023-03-21 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
CN110144009B
(zh)
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
KR102490850B1
(ko)
|
2018-02-26 |
2023-01-26 |
메디진 이뮤노테라피스 게엠바하 |
Nyeso t 세포 수용체
|
EA202091710A1
(ru)
|
2018-03-09 |
2021-02-16 |
Агенус Инк. |
Антитела против cd73 и способы их применения
|
JP2021517130A
(ja)
|
2018-03-13 |
2021-07-15 |
オーセ イミュノセラピューティクスOse Immunotherapeutics |
抗ヒトSIRPav1抗体の使用および抗v1抗体を製造する方法
|
WO2019179366A1
(en)
|
2018-03-20 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-cd47 antibodies
|
WO2019183266A1
(en)
|
2018-03-21 |
2019-09-26 |
ALX Oncology Inc. |
Antibodies against signal-regulatory protein alpha and methods of use
|
CN110305212A
(zh)
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
CN110386984B
(zh)
|
2018-04-17 |
2022-04-22 |
杭州尚健生物技术有限公司 |
结合cd47蛋白的融合蛋白及其应用
|
KR20210003767A
(ko)
|
2018-04-19 |
2021-01-12 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도
|
CN110577597B
(zh)
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技(成都)有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
EP3806901A4
(en)
|
2018-06-15 |
2022-06-22 |
Accurus Biosciences, Inc. |
BLOCKING ANTIBODIES AGAINST CD47 AND THEIR METHODS OF USE
|
WO2020009725A1
(en)
|
2018-07-05 |
2020-01-09 |
Trican Biotechnology Co., Ltd |
Human anti-cd47 antibodies and uses thereof
|
TW202035449A
(zh)
|
2018-07-10 |
2020-10-01 |
國立大學法人神戶大學 |
抗SIRPα抗體
|
CN112399874B
(zh)
|
2018-07-13 |
2024-03-22 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
WO2020019135A1
(zh)
|
2018-07-23 |
2020-01-30 |
中国科学院微生物研究所 |
一种抗cd47抗体及其应用
|
WO2020036977A1
(en)
|
2018-08-13 |
2020-02-20 |
Arch Oncology, Inc. |
Therapeutic cd47 antibodies
|
CN110835371A
(zh)
*
|
2018-08-19 |
2020-02-25 |
普米斯生物技术(苏州)有限公司 |
抗ccr8单克隆抗体及其应用
|
EP3845561A4
(en)
|
2018-08-31 |
2022-07-06 |
Nanjing Sanhome Pharmaceutical Co., Ltd. |
ANTI-CD47 ANTIBODIES AND ITS USE
|
WO2020086158A2
(en)
|
2018-09-05 |
2020-04-30 |
The Regents Of The University Of California |
Composition of ny-eso-1-specific t cell receptors restricted on multiple major histocompatibility complex molecules
|
CN110950949B
(zh)
|
2018-09-26 |
2022-04-05 |
香雪生命科学技术(广东)有限公司 |
一种识别ssx2抗原的t细胞受体
|
MX2021003393A
(es)
|
2018-09-27 |
2021-05-13 |
Celgene Corp |
Proteinas de fijacion a sirp alfa y metodos de uso de estas.
|
KR20200040407A
(ko)
|
2018-10-10 |
2020-04-20 |
주식회사 노벨티노빌리티 |
신규 항-c-KIT 항체
|
KR20210093908A
(ko)
|
2018-10-23 |
2021-07-28 |
리제너론 파아마슈티컬스, 인크. |
Ny-eso-1 t 세포 수용체 및 이의 사용 방법
|
CA3116347A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
IL282535B2
(en)
|
2018-10-31 |
2024-05-01 |
Gilead Sciences Inc |
Transformed 6-azabanzimidazole compounds as HPK1 inhibitors
|
CA3117816A1
(en)
|
2018-11-26 |
2020-06-04 |
Forty Seven, Inc. |
Humanized antibodies against c-kit
|
MX2021007576A
(es)
|
2018-12-27 |
2021-08-24 |
Shionogi & Co |
Nuevo anticuerpo anti receptor 8 de motivo c-c de quimiocina (ccr8).
|
PE20220231A1
(es)
|
2019-06-25 |
2022-02-07 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso
|
CA3169451A1
(en)
|
2020-02-14 |
2021-08-19 |
Jounce Therapeutics, Inc. |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
CN115551895A
(zh)
|
2020-03-05 |
2022-12-30 |
纪念斯隆凯特琳癌症中心 |
抗ccr8剂
|
JP2023519254A
(ja)
|
2020-03-23 |
2023-05-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
がんを処置するための抗ccr8抗体
|
TW202216771A
(zh)
|
2020-06-26 |
2022-05-01 |
德商拜耳廠股份有限公司 |
用於治療應用之ccr8抗體
|
JPWO2022004760A1
(es)
|
2020-06-30 |
2022-01-06 |
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
WO2022000443A1
(en)
|
2020-07-03 |
2022-01-06 |
Nanjing Immunophage Biotech Co., Ltd. |
Methods and compositions for targeting tregs using ccr8 inhibitors
|
JP2023538782A
(ja)
|
2020-08-28 |
2023-09-11 |
ハーバー・バイオメド・ユーエス・インコーポレイテッド |
Ccr8抗体及びその用途
|
CA3198456A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
CN115052892B
(zh)
|
2020-10-16 |
2023-07-07 |
礼新医药科技(上海)有限公司 |
抗ccr8单克隆抗体及其用途
|
WO2022117569A1
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
|
WO2022136650A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Murine cross-reactive human ccr8 binders
|
WO2022136647A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Human ccr8 binders
|
EP4267618A1
(en)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Non-blocking human ccr8 binders
|
JP2024512567A
(ja)
|
2021-03-23 |
2024-03-19 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
T細胞リンパ腫の診断および治療方法
|
WO2022216965A1
(en)
|
2021-04-07 |
2022-10-13 |
Actinium Pharmaceuticals, Inc. |
Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells
|
CN117597364A
(zh)
|
2021-05-12 |
2024-02-23 |
百进生物科技公司 |
抗ccr8抗体、其抗原结合片段、以及试剂和组合物及其制备和使用方法
|
WO2023288241A1
(en)
|
2021-07-14 |
2023-01-19 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
BR112023024837A2
(pt)
|
2021-07-27 |
2024-02-20 |
Abbvie Inc |
Anticorpos anti-ccr8
|
KR20240046533A
(ko)
|
2021-08-20 |
2024-04-09 |
하이파이바이오 인코퍼레이티드 |
항-ccr8 항체 및 그것의 용도
|